ReviewFrontiers in immunology2014
CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis.Frontiers in oncology · 2022Pooled it
- Neuromodulation influences T lymphocyte calcium signaling and alpha synuclein clearance: implications for Parkinson's disease.Frontiers in cellular neuroscience · 2025Review
- The Impact of Liver Steatosis on Interleukin and Growth Factors Kinetics during Chronic Hepatitis C Treatment.Journal of clinical medicine · 2024Article
- Single-cell adhesive profiling in an optofluidic device elucidates CD8Cell reports methods · 2024Article
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
- Non-Classical HLA Class 1b and Hepatocellular Carcinoma.Biomedicines · 2023Review
- The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.Vaccines · 2021Review
- Immune system control of hepatitis C virus infection.Current opinion in virology · 2021Review
- Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3.Frontiers in microbiology · 2020Article
- A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice.BMC infectious diseases · 2019Article
- [Study of tumor necrosis factor receptor superfamily 1B gene polymorphism in relation to the outcomes of HCV infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
- Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship.Hepatology (Baltimore, Md.) · 2019Review
- Sex Differences in Mouse Popliteal Lymph Nodes.Scientific reports · 2019Article
- Inhibitory killer cell immunoglobulin-like receptors strengthen CD8Science immunology · 2018Article
- Hitting the Target: How T Cells Detect and Eliminate Tumors.Journal of immunology (Baltimore, Md. : 1950) · 2018Review
- Article
- A Mouse Model of Autoimmune Cholangitis via Syngeneic Bile Duct Protein Immunization.Scientific reports · 2017Article
- Dynamics of the Immune Response in Acute Hepatitis B Infection.Open forum infectious diseases · 2017Article
- Immune responses and immunopathology in acute and chronic viral hepatitis.Nature reviews. Immunology · 2016Review
- Immunological changes in different patient populations with chronic hepatitis C virus infection.World journal of gastroenterology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infects approximately 170 million people worldwide and is a major cause of life-threatening liver diseases such as liver cirrhosis and hepatocellular carcinoma. Acute HCV infection often progresses to chronic persistent infection, although some patients recover spontaneously. The divergent outcomes of acute HCV infection are known to be determined by differences in virus-specific T-cell responses among patients. Of the two major T-cell subsets, CD8(+) T-cells are known to be the key effector cells that control viral infections via cytolytic activity and cytokine secretion. Herein, we review various aspects of HCV-specific CD8(+) T-cell responses in acute HCV infection. In particular, we focus on timing of CD8(+) T-cell responses, relationship between CD8(+) T-cell responses and outcomes of acute HCV infection, receptor expression on CD8(+) T-cells, breadth of CD8(+) T-cell responses, and viral mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.